Newsroom | 96465 results

NUEVA YORK--(BUSINESS WIRE)--Blue Matter tiene el orgullo de anunciar que ha establecido un área de práctica que prestará exclusivamente servicios a los clientes en investigación y desarrollo (I+D) biofarmacéutico. La dirección de esta práctica estará a cargo de Tara Austraat-Churik, una socia que se incorporó a la firma en septiembre de 2025. Tara Austraat-Churik tiene más de 20 años de experiencia en servicios a los clientes del sector de las ciencias de la vida. Se ha especializado en las ár...

NEW YORK--(BUSINESS WIRE)--Blue Matter a le plaisir d'annoncer la création d'un domaine d'expertise dédié aux clients du secteur de la recherche et développement biopharmaceutique. Ce domaine est dirigé par l'associée Tara Austraat-Churik, qui a rejoint le cabinet en septembre 2025. Tara Austraat-Churik accompagne les acteurs des sciences de la vie depuis plus de 20 ans. Ses domaines d'expertise comprennent le développement et la mise en œuvre de stratégies, la conception de modèles opérationne...

NEW YORK--(BUSINESS WIRE)--Blue Matter annuncia la creazione di una nuova area di consulenza dedicata ai clienti del settore R&S biofarmaceutico e diretta da Tara Austraat-Churik, partner unitasi a Blue Matter nel settembre 2025. Tara Austraat-Churik vanta un’esperienza di oltre 20 anni al servizio di clienti nel settore delle scienze della vita. Molteplici le sue aree di competenza – sviluppo e implementazione di strategie, progettazione di modelli operativi e organizzativi, ottimizzazione...

NEW YORK--(BUSINESS WIRE)--Blue Matter hat einen neuen Praxisbereich gegründet, der auf die Bedürfnisse von Kunden aus der biopharmazeutischen Forschung und Entwicklung (FuE) ausgerichtet ist. Geleitet wird der Praxisbereich von Tara Austraat-Churik, einer Partnerin, die seit September 2025 für Blue Matter tätig ist. Tara Austraat-Churik ist bereits seit über 20 Jahren für Life-Science-Kunden tätig. Ihre Schwerpunkte sind Strategieentwicklung und -umsetzung, Betriebsmodell- und Organisationsges...

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14...

ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction...

BOUNTIFUL, Utah--(BUSINESS WIRE)--Vy Spine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VyBrate VBR System which is designed for use in both the cervical and thoracolumbar spine for vertebral body replacement surgery. The VyBrate VBR is an innovative device combining the osseointegration properties of the OXPEKK material and the novel OsteoVy lattice structure...

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit o...